New 2023 CTS COPD Pharmacotherapy Guideline: Time to Act in Everyday Practice
New 2023 CTS COPD Pharmacotherapy Guideline:
Time to Act in Everyday Practice
Speaker: Dr. Jean Bourbeau MD, MSc, FRCP, FCAHS
Respirologist at the Montreal Chest Institute of the MUHC
Senior Scientist at the RIMUHC
At the end of the presentation, the audience will:
Summarize the new recommendations based on evidence of the pharmacotherapy of stable COPD patients for the following outcomes:
路 Alleviating symptoms (dyspnea) and improving health status
路 Preventing exacerbations
路 Reducing mortality
2. Apply a comprehensive management of COPD and a new 鈥減harmacotherapy pathway鈥� for individuals with stable COPD.
3. Understand the benefit risk approach in the prescription of ICS containing regimen
4. Fill the gap for optimal treatment strategies in the real world practice
听
Zoom link: